期刊文献+

41℃及43℃温热疗联合聚乙二醇化脂质体阿霉素治疗兔VX2肿瘤的疗效对比研究 被引量:1

Comparative study on efficacy of 41 ℃ or 43 ℃ mild hyperthermia with pegylated liposomal doxorubicin for treatment of rabbit VX2 tumor
下载PDF
导出
摘要 目的探讨41℃及43℃温热疗(MH)触发聚乙二醇化脂质体阿霉素(PLD)释放阿霉素治疗兔VX2肿瘤的疗效差异。方法 12只VX2移植瘤兔随机分为2组:PLD+41℃MH组(n=6)和PLD+43℃MH组(n=6)。为达到完全的肿瘤缓解,进行多次高剂量耳缘静脉推注给药(5 mg/kg,每周1次,共治疗3次),使用嵌入式超声温热治疗仪对肿瘤部位进行30 min局部MH。结果在观察终点,PLD+41℃MH组血管形成指数(VI)、瘤体质量、外周血谷草转氨酶(GOT)、乳酸脱氢酶(LDH)、肌酸激酶(CPK)值均明显低于PLD+43℃MH组。结论同43℃下30 min MH相比,41℃下30 min MH联合PLD可以明显提高抗肿瘤疗效,降低系统毒性。 Objective To investigate the difference in efficacy between doxorubicin released by 41 ℃ and 43 ℃mild hyperthermia(MH) triggered-pegylated liposomal doxorubicin(PLD) for the treatment of rabbit VX2 tumor.Methods Twelve rabbits with VX2 tumor transplanted into the superficial muscle of the hind limb were randomly assigned to 2 groups,i.e.the 41 ℃ MH + PLD group(n= 6) and the 43 ℃ MH +PLD group(n=6).To achieve complete tumor remission,multiple high-dose administrations(5 mg/kg,once per week for3 weeks) were given by intravenous injection.An embedded ultrasound tumor hyperthermia instrument was used to perform local M H at tumor sites for 30 min.Results At the endpoint,the 41 ℃ MH + PLD group had lower vascularization index,tumor weight,and levels of GOT,LDH and CPK in peripheral blood as compared with the 43 ℃ MH +PLD group.Conclusion In comparison with 43 ℃ MH for 30 min,41 ℃MH for 30 min plus PLD can significantly improve the antitumor efficacy,and reduce the systemic toxicity.
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2016年第6期799-802,共4页 Journal of Shanghai Jiao tong University:Medical Science
基金 国家自然科学基金(81272567)~~
关键词 聚乙二醇化脂质体阿霉素 温热疗 VX2肿瘤模型 pegylated liposomal doxorubicin mild hyperthermia VX2 tumor model
  • 相关文献

参考文献21

  • 1Seynhaeve AL, Dicheva BM, Hoving S, et al. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosorne: evaluated by in vitro/in vivo live cell imaging[J]. J Control Release, 2013, 172(1) : 330 -340.
  • 2Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility[ J]. J Control Release, 2011, 153 (3) : 198 - 205.
  • 3Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors [J]. Nat Rev ClinOncol, 2010, 7(11):653-664.
  • 4Kong G, Braun RD, Dewhirst MW. ltyperthermia enables tumor- specific nanoparticle delivety: effect of particle size [ J]. Cancer Res, 2000, 60(16): 4440-4445.
  • 5Tagami T, May JP, Ernsting MJ, et al. A thermosensitive liposome prepared with a Cu2 + gradient demonstrates improved pharmacoki- netics, drug delivery and antitumor efficacy[ J]. J Control Release, 2012, 161(1) : 142 - 149.
  • 6Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: phar- macodynamics and adverse effects [ J ]. Pharmacogenet Genomics, 2011, 21(7): 440-446.
  • 7Allen TM, Cullis PR. Drug delivery systems: entering the main- stream[J]. Science, 2004, 303(5665): 1818-1822.
  • 8Duggan ST, Keating GM. Pegylated liposomal doxorubiein: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma[ J]. Drugs, 2011, 71 (18): 2531 -2558.
  • 9O'Brien ME, Wigler N, lnbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase Ⅲ trial of pegylated liposomal doxorubicin HC1 (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer[ J]. Ann Oncol, 2004, 15(3) : 440 -449.
  • 10Seynhaeve AL, Hoving S, Sehipper D, et al. Tumor necrosis factor a mediates homogeneous distribution of liposomes in marine melanoma that contributes to a beMHer tumor response[ J ]. Cancer Res, 2007, 67(19): 9455-9462.

同被引文献10

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部